These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8913427)

  • 1. Comment: delayed risperidone-induced neuroleptic malignant syndrome.
    Sitarz WE
    Ann Pharmacother; 1996 Nov; 30(11):1342-3. PubMed ID: 8913427
    [No Abstract]   [Full Text] [Related]  

  • 2. Serotonin syndrome during treatment with paroxetine and risperidone.
    Hamilton S; Malone K
    J Clin Psychopharmacol; 2000 Feb; 20(1):103-5. PubMed ID: 10653219
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroleptic malignant syndrome following administration of risperidone and lithium.
    Bourgeois JA; Kahn DR
    J Clin Psychopharmacol; 2003 Jun; 23(3):315-7. PubMed ID: 12826996
    [No Abstract]   [Full Text] [Related]  

  • 4. Risperidone and neuroleptic malignant syndrome.
    Tarsy D
    JAMA; 1996 Feb; 275(6):446. PubMed ID: 8627964
    [No Abstract]   [Full Text] [Related]  

  • 5. Neuroleptic malignant syndrome with risperidone.
    Gleason PP; Conigliaro RL
    Pharmacotherapy; 1997; 17(3):617-21. PubMed ID: 9165568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Malignant neuroleptic syndrome associated to risperidone].
    Aguirre C; García Monco JC; Mendibil B
    Med Clin (Barc); 1998 Feb; 110(6):239. PubMed ID: 9547739
    [No Abstract]   [Full Text] [Related]  

  • 7. [Malignant neuroleptic syndrome in treatment with the new, atypical antipsychotic agents, risperidone and olanzapine].
    Gram LF
    Ugeskr Laeger; 2000 Mar; 162(13):1914-5. PubMed ID: 10765710
    [No Abstract]   [Full Text] [Related]  

  • 8. Neuroleptic malignant syndrome after addition of paroxetine to olanzapine.
    Kontaxakis VP; Havaki-Kontaxaki BJ; Pappa DA; Katritsis DE; Christodoulou GN
    J Clin Psychopharmacol; 2003 Dec; 23(6):671-2. PubMed ID: 14624202
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroleptic malignant syndrome following combination of sertraline and paroxetine: a case report.
    Uguz F; Sonmez EÖ
    Gen Hosp Psychiatry; 2013; 35(3):327.e7-327.e8. PubMed ID: 23312145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuroleptic malignant syndrome associated with amoxapine and lithium in an older adult.
    Gupta S; Racaniello AA
    Ann Clin Psychiatry; 2000 Jun; 12(2):107-9. PubMed ID: 10907803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of Parkinson's disease with neuroleptic malignant syndrome induced by paroxetine].
    Hamada Y; Miyamoto K; Inatsugi Y; Suzuki H; Kusunoki S
    Rinsho Shinkeigaku; 2006 Aug; 46(8):575-8. PubMed ID: 17154040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Life-threatening serotonin syndrome following a single dose of a serotonin reuptake inhibitor during maintenance therapy with a monoamine oxidase inhibitor].
    Güzelcan Y; Kleinpenning AS
    Ned Tijdschr Geneeskd; 2006 Aug; 150(31):1748; author reply 1748-9. PubMed ID: 16927475
    [No Abstract]   [Full Text] [Related]  

  • 13. Combination risperidone and SSRI-induced serotonin syndrome.
    Karki SD; Masood GR
    Ann Pharmacother; 2003 Mar; 37(3):388-91. PubMed ID: 12639169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fatal neuroleptic malignant syndrome in a previously long-term user of clozapine following its reintroduction in combination with paroxetine.
    Gambassi G; Capurso S; Tarsitani P; Liperoti R; Bernabei R
    Aging Clin Exp Res; 2006 Jun; 18(3):266-70. PubMed ID: 16804375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genotype A1/A2 associated with neuroleptic malignant syndrome.
    Del Tacca M; Lattanzi L; Lastella M; Di Paolo A; Mungai F; Danesi R; Menichetti F; Dell'osso L; Cassano GB
    Bipolar Disord; 2005 Aug; 7(4):390-1. PubMed ID: 16026494
    [No Abstract]   [Full Text] [Related]  

  • 16. Neurotoxic syndrome associated with risperidone and fluvoxamine.
    Reeves RR; Mack JE; Beddingfield JJ
    Ann Pharmacother; 2002 Mar; 36(3):440-3. PubMed ID: 11895057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serotonin syndrome versus neuroleptic malignant syndrome: a challenging clinical quandary.
    Dosi R; Ambaliya A; Joshi H; Patell R
    BMJ Case Rep; 2014 Jun; 2014():. PubMed ID: 24957740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamic and pharmacokinetic factors in a case of neuroleptic malignant syndrome.
    Shad MU; Preskorn SH
    J Clin Psychopharmacol; 1998 Aug; 18(4):346-7. PubMed ID: 9690705
    [No Abstract]   [Full Text] [Related]  

  • 19. Neuroleptic malignant syndrome caused by combination of risperidone and lithium in a patient with multiple medical comorbidities.
    Kosehasanogullari SG; Akdede B; Akvardar Y; Akan M; Tunca Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1147-8. PubMed ID: 17513032
    [No Abstract]   [Full Text] [Related]  

  • 20. Neuroleptic malignant syndrome due to risperidone treatment in a child with Joubert syndrome.
    Vurucu S; Congologlu A; Altun D; Unay B; Akin R
    J Natl Med Assoc; 2009 Mar; 101(3):273-5. PubMed ID: 19331262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.